Home / Resources / Videos / ADA 2017 / Carla Greenbaum Part 6, Advancing Disease Therapy In Type 1 Diabetes

Carla Greenbaum Part 6, Advancing Disease Therapy In Type 1 Diabetes




In part 6 of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what health care providers can do for people with type 1.

Carla Greenbaum, MD is Director of the Diabetes Research Program at Benaroya Research Institute at Virginia Mason in Seattle, WA.

Transcript of this video segment:

Steve Freed: Speaking of the diabetic healthcare provider, due to advance disease modifying therapy in type 1 diabetes, what can we do?

Carla Greenbaum: Yeah, that’s a great question because one of the challenges we have is that we know that even experienced diabetes healthcare providers, don’t seem to know that the risk, once somebody has diabetes, is 15 times greater. So, the first thing they need to do, every time they have someone who has diabetes in their family, they need to tell them. The other family members are at increased risk and they can refer them and get them tested. We now have [ways] people can sign up and do this online. Go to Diabetestrialnet.org and people can read about the studies, decide whether they want to participate. Or even instituting, hopefully by the end of this year, where people have kits at home and they can test finger sticks and send us a blood samples at home. So I think from a healthcare provider standpoint, you should be aware that these studies are going on. You need to let people know that their risk is increased, refer them for the studies and not be so scared about immune therapy. These are used in many, many, many diseases. 80 million Americans take immune therapy and it’s very effective in changing the course of their disease and we need to offer that to people with diabetes.

Return to the main page.